6 terminated. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 6 |
| Phase 2 | 4 | Terminated 4 |
Follow Chorea: new trials by email Literature Review of Chorea trials Research Report on Chorea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD Deutetrabenazine Oral Tablet [Austedo], Placebo oral tablet - Huntington Disease | Phase 1 | Terminated | Fundacion Huntington Puerto Rico | 36 | 2022-01-21 | 2025-02-27 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease WVE-120101 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 27 | 2020-04-13 | 2022-02-09 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease WVE-120102 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 36 | 2019-09-24 | 2022-02-09 |
| Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease WVE-120101, Placebo - Huntington's Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 61 | 2017-07-17 | 2022-02-10 |
| Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease WVE-120102, Placebo - Huntington's Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 88 | 2017-07-17 | 2022-04-25 |
| Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers PBF-999 / 160 mg, PBF-999 / 320 mg, Placebo - Huntington Disease | Phase 1 | Terminated | Palobiofarma SL | 8 | 2016-03-01 | 2016-09-20 |
Huntington Disease (6) · Mental Disorders (1)
Basal Ganglia Diseases (6) · Brain Diseases (6) · Central Nervous System Diseases (6) · Cognition Disorders (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Dementia (6) · Dyskinesias (6) · Genetic Diseases, Inborn (6) · Heredodegenerative Disorders, Nervous System (6) · Movement Disorders (6) · Nervous System Diseases (6) · Neurocognitive Disorders (6) · Neurodegenerative Diseases (6) · Mental Disorders (5)
deutetrabenazine (1)
Wave Life Sciences USA, Inc. (4) · Fundacion Huntington Puerto Rico (1) · Palobiofarma SL (1)
Australia (4) · Canada (4) · Denmark (4) · France (4) · Germany (4) · Poland (4) · United Kingdom (4) · Puerto Rico (1) · Spain (1) · United States (1)
2015 (1)